Key result
Dasatinib and quercetin improve contractility and reduce passive tension in engineered human cardiac fibrotic tissues.
Why the study?
Cardiac fibrosis contributes significantly to heart failure, and standard-of-care drugs have had limited ability to reverse associated functional impairment in human-relevant models.
Does treatment with senolytic drugs dasatinib and quercetin improve contractile function and reduce senescence in a human model of cardiac fibrosis-on-a-chip?
Does treatment with senolytic drugs dasatinib and quercetin improve contractile function and reduce senescence in a human model of cardiac fibrosis-on-a-chip?
Senolytic therapy with dasatinib and quercetin improves contractile function and reduces senescence markers in a human heart-on-a-chip model of cardiac fibrosis.
May support senolytic testing in cardiac fibrosis models; leaves open clinical translation from this in vitro evidence.
Cardiac fibrosis is a significant contributor to heart failure and is characterized by abnormal ECM deposition and impaired contractile function. We have previously developed a model of cardiac fibrosis via TGF-β treatment of engineered microtissues using heart-on-a-chip technology which incorporates human induced pluripotent stem cell-derived cardiomyocytes and cardiac fibroblasts. Here, we describe that these cardiac fibrotic tissues expressed markers associated with cellular senescence via transcriptomic analysis. Treatment of fibrotic tissues with the senolytic drugs dasatinib and quercetin (D+Q) led to an improvement of contractile function, reduced passive tension, and downregulated senescence-related gene expression, an outcome we were previously unable to achieve using standard-of-care drugs. The improvement in functional parameters was also associated with a reduction in fibroblast density, though no changes in absolute collagen deposition were observed. This study demonstrates the benefit of senolytic treatment for cardiac fibrosis in a human-relevant model, supporting data in animal models, and will enable the further elucidation of cell-specific effects of senolytics and how they impact cardiac fibrosis and senescence.
No takes yet. Share an insight, caveat, or question.
Mourad et al. (2023) studied Cardiac fibrosis. Dasatinib and quercetin (D+Q) vs. Standard-of-care drugs / untreated was evaluated on Contractile function, passive tension, and senescence-related gene expression. Treatment of engineered human cardiac fibrotic tissues with dasatinib and quercetin improved contractile function and reduced passive tension, though absolute collagen deposition was unchanged.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: